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Abstract
Background: We previously reported mass spectrometry-based proteomic discovery research to identify novel
plasma proteins related to the risk of coronary heart disease (CHD) and stroke, and to identify proteins with
concentrations affected by the use of postmenopausal hormone therapy. Here we report CHD and stroke risk
validation studies for highly ranked proteins, and consider the extent to which protein concentration changes relate
to disease risk or provide an explanation for hormone therapy effects on these outcomes.
Methods: Five proteins potentially associated with CHD (beta-2 microglobulin (B2M), alpha-1-acid glycoprotein 1
(ORM1), thrombospondin-1(THBS1), complement factor D pre-protein (CFD), and insulin-like growth factor binding
protein 1 (IGFBP1)) and five potentially associated with stroke (B2M, IGFBP2, IGFBP4, IGFBP6, and hemopexin (HPX))
had high discovery phase significance level ranking and an available ELISA assay, and were included in case-control
validation studies within the Women’s Health Initiative (WHI) hormone therapy trials. Protein concentrations, at
baseline and 1 year following randomization, were assessed for 358 CHD cases and 362 stroke cases, along with
corresponding disease-free controls. Disease association, and mediation of estrogen-alone and estrogen plus
progestin effects on CHD and stroke risk, were assessed using logistic regression.
Results: B2M, THBS1, and CFD were confirmed (P <0.05) as novel CHD risk markers, and B2M, IGFBP2, and IGFBP4
were confirmed as novel stroke disease risk markers, while the assay for HPX proved to be unreliable. The change
from baseline to 1 year in B2M was associated (P <0.05) with subsequent stroke risk, and trended similarly with
subsequent CHD risk. Change from baseline to 1 year in IGFBP1 was also associated with CHD risk, and this change
provided evidence of hormone therapy effect mediation.
Conclusions: Plasma B2M is confirmed to be an informative risk marker for both CHD and stroke. The B2M increase
experienced by women during the first year of hormone therapy trial participation conveys cardiovascular disease
risk. The increase in IGFBP1 similarly conveys CHD risk, and the magnitude of the IGFBP1 increase following
hormone therapy may be a mediator of hormone therapy effects. Plasma THBS1 and CFD are confirmed as CHD
risk markers, and plasma IGFBP4 and IGFBP2 are confirmed as stroke risk markers.
Clinical trials registration: ClinicalTrials.gov identifier: NCT00000611
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Cardiovascular disease (CVD), particularly coronary
heart disease and stroke, remains the leading cause of
death in the United States among both women and men
in all racial and ethnic groups. CHD is the designated
cause for about 25% of all deaths and stroke for an
additional 12% [1]. Risk factor epidemiology has played a
crucial role in attempts to understand CVD mechanisms
and pathways, and has led to the identification of
effective approaches to disease prevention, for example
through the treatment of hypertension [2], hypercholes-
terolemia [3], and arguably chronic inflammation [4].
Risk factor data, such as those arising from the
Framingham Study cohort, have been effectively used
to develop risk prediction models for CHD [5,6] and
for stroke [7,8].
Both the age-incidence pattern and the strength of as-
sociation for some risk factors differ between women
and men, and it has been standard procedure to study
CVD risk factors and risk prediction models in a sex-
specific manner. Some studies have examined the ability
of non-traditional risk factors to add to discrimination
between CVD cases and controls. For example, an
ischemic stroke study [9] showed that the estimated
area under the receiver-operator-characteristic curve
(AUC) among women in the Atherosclerosis Risk in
Communities cohort increased from 0.83 to only 0.84
when certain non-traditional risk markers were included.
Corresponding numbers were 0.76 and 0.80 among men.
A study of CHD risk prediction models [10] in the
Women’s Health Initiative (WHI) postmenopausal hor-
mone therapy (HT) trial cohort found that the AUC in-
creased from 0.73 to 0.75 when certain non-traditional
risk factors were added. While these analyses imply an
ability to assign CHD and stroke risk estimates that vary
by several-fold among individuals, there is still a limited
ability to identify individuals who are highly likely to
develop disease, say, in the next 5 years. Additional
blood-based biomarkers may lead to improvements in
risk discrimination and risk prediction.
Blood biomarkers also have potential to provide bio-
logical insights into the effects of interventions on CVD
outcomes. In particular, the pathways influenced and the
key mediators of the effects of postmenopausal estrogen
(E-alone) and estrogen plus progestin (E +P) on CVD
remain substantially unknown. In the WHI randomized
controlled trials these effects include an early elevation
of CHD risk with E +P [11] that was less apparent for
E-alone [12], and sustained elevations in stroke risk, of a
similar magnitude with E +P [13] and E-alone [14].
We have carried out proteomic discovery work using
an Intact Protein Analysis System [15] to compare, for
about 370 proteins, pre-diagnostic plasma concentra-
tions between CHD cases and matched controls, and
between stroke cases and matched controls, drawn from
the WHI Observational Study cohort [16]. We con-
firmed [17] the associations of beta-2-microglobulin
(B2M) with short-term CHD risk, and the association of
insulin-like growth factor-binding protein 4 (IGFBP4)
with short-term stroke risk by comparing baseline blood
concentrations for these proteins among women devel-
oping these diseases during the first year of participation
in the WHI HT trials to 1-1 matched controls, using
enzyme-linked immunosorbent assays (ELISAs). The as-
sociation of these markers with longer-term CHD and
stroke risk has yet to be studied. Importantly, there were
several other proteins having empirical support for CHD
or stroke risk association in our discovery research, with
commercially available ELISAs. Here we report on these
proteins collectively in relation to CHD and stroke inci-
dence in the WHI HT trials, both as novel disease risk
markers and as potential mediators of corresponding
postmenopausal HT effects on CHD and stroke risk.
Methods
Study subjects and outcome ascertainment
Women who were postmenopausal and in the age range
of 50-79 years enrolled in the WHI HT trials during
1993 to 1998, including 10,739 women who were post-
hysterectomy in the E-alone trial and 16,608 women
with uterus in the E+ P trial. Of these, women who ex-
perienced CHD or stroke through February 2001 were
included in a CVD biomarker case-control study [18,19].
Controls who were free of CVD through this date were
matched 1-1 to cases on age, randomization date,
hysterectomy status, and prevalent study disease at base-
line in each trial. These cases and controls were well-
characterized in terms of traditional risk factors. One
hundred incident stroke cases arising during subsequent
HT trial follow-up, and 1-1 matched controls using the
same matching criteria, were subsequently added to en-
hance the ability to study the two diseases separately. A
small number of the selected controls developed the dis-
ease of their matched case by the end of the planned
trial intervention phase (8 April 2005) and are included
in the case group here, giving a total of 358 CHD cases
and a corresponding 352 controls, and a total of 362
stroke cases and a corresponding 346 matched controls
for whom baseline plasma protein concentrations were
assessed. Of these, 106 CHD cases and 68 stroke cases
had their disease events during the first year following
randomization. For all other cases and controls plasma
protein concentrations were also assessed from blood
drawn at 1 year following randomization.
CHD in the HT trials is defined as non-fatal myocar-
dial infarction (MI) or death due to coronary heart
disease. Disease event ascertainment involved physician
adjudication based on the review of pertinent documents
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tral committee [20] with agreement rates of 90% for MI
and 97% for death due to coronary heart disease,
between local and central adjudication. Cases of hospi-
talized stroke were based on rapid neurologic deficit
attributable to arterial obstruction or rupture, or a
demonstrable lesion compatible with acute stroke [13].
Central neurologists reviewed all stroke cases, as well as
transient ischemic attacks and self-reports of stroke.
Strokes were classified as ischemic or hemorrhagic, as
well as according to various outcome scales.
All participants provided written informed consent for
their HT trial and their overall WHI participation. The
related protocols were approved by the Institutional
Review Board of the Fred Hutchinson Cancer Research
Center and each of the 40 participating clinical centers.
The research was conducted in accordance with the
Helsinki Declaration and with pertinent local legislation.
Specimen preparation and analysis
Fasting blood specimens were obtained at baseline in
WHI as a part of eligibility screening and at 1 year fol-
lowing randomization, for clinical trial women. Serum
and plasma were sent to a central laboratory and stored
at -70°C. Plasma specimens for this project were plated
so that case and matched control specimens were
analyzed together. For cases occurring after the first
year from randomization, the 1-year plasma specimens
were plated with baseline specimens for concurrent
ELISA analyses. Assays for each plasma sample followed
ELISA kit manufacturer (R and D Systems, Minneapolis,
MN, USA, for IGFBP1, IGFBP2, IGFBP4, IGFBP6,
ORM1, THBS1, and CHD; CalBiotech, Spring Valley,
CA, USA, for B2M; Abnova, Taipei, Taiwan, for HPX)
recommendations. All samples were assayed with sample
characteristics blinded, and in duplicate. Quality control
activities included 5% blind duplicate analyses, using
plasma from postmenopausal women outside of the HT
trial cohorts. The reliability of the ELISA measurements
was assessed by examining intra-class correlations be-
tween blind duplicates. Each protein concentration was
reliably measured, with intra-class correlations ranging
from 0.79 to 0.97, with the exception of HPX where the
intra-class correlation was 0.38. Linear dilution curves
were examined and a dilution was selected for each
analyte that was above the detection threshold and
below saturation. The dilutions applied were 1:50, 1:10,000,
1:1,500, 1:3,000, and 1:25 for B2M, ORM1, THSB1, CFD,
and IGFBP1, respectively; and 1:250, 1:50, 1:500, and 1:400
for IGFBP2, IGFBP4, IGFBP6, and HPX, respectively.
Proteomic biomarker selection
The in-depth proteomic discovery methodology [15,21]
led to nine proteins in a false discovery rate (FDR) bin
[22] of less than 20% for CHD and 11 such proteins for
stroke [17]. Of these B2M, ORM1, THBS1, CFD, and
IGFBP1 were selected on the basis of not being estab-
lished as CHD risk markers, and having commercially
available ELISA assays. The same criteria applied to the
novel stroke candidates led to the selection of IGFBP2,
IGFBP4, and IGFBP6, and HPX. B2M was also assessed
for stroke cases and controls, based on its CHD associ-
ation and a nominal P value of 0.03, even though FDR
bin was higher (0.31) for this protein.
The CVD proteomic discovery work was complemen-
ted by additional IPAS analyses comparing blood protein
concentrations at baseline and at 1 year following
randomization for 50 women who adhered to active
intervention during the first year of the E-alone trial
[23], and 50 women who adhered to active intervention
in the E +P trial [24]. These analyses suggested many
proteomic changes following 1 year of use of these prep-
arations, with 169 (44.7%) of the 378 proteins quantified
having some evidence (nominal P <0.05) of change for
one or both of E-alone or E +P [24]. Proteins with chan-
ged concentrations contributed to multiple biologic
pathways relevant to the observed clinical effects of HT,
including coagulation, inflammation, immune response,
metabolism, cell adhesion, growth factors, and osteogen-
esis. The estimated 1-year versus baseline concentration
ratios were very similar for E-alone and E +P for most
highly ranked proteins, supporting the notion of com-
bining proteomic analyses across the two trials.
Of the risk marker candidates selected here, B2M,
CFD, and IGFBP1 for CHD, and each of the five proteins
selected for stroke were among the proteins whose con-
centrations were observed to change (nominal P <0.05)
as a result of HT [24].
Statistical methods
Principal association analysis estimated CHD or stroke
odds ratios (ORs) as a function of log-transformed baseline
biomarker values using binary logistic regression of case (1)
versus control (0) status [25]. For either disease, the logistic
regression model also included systolic and diastolic blood
pressure, cigarette smoking, diabetes, prior HT use, and
body mass index, as well as the case-control matching fac-
tors (age, hysterectomy status, randomization year, prior
history of study disease).
Analyses to examine the extent to which treatment-
related changes in protein concentrations between base-
line and 1 year following randomization can provide an
explanation for E-alone and E +P effects on CHD and
stroke, also relied on binary logistic regression. Analyses
of the type just described, but based on cases occurring
after the first year from HT trial enrollment and all con-
trols for the specific trial, were carried out to estimate
HT effects on disease OR and to examine the possibility
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level of a biomarker under study. A biomarker mediation
analysis then proceeded by adding the (log-transformed)
year 1 biomarker value or equivalently, the logarithm of
the year 1-to-baseline biomarker ratio, to the regression
model, and examining the change in the HT OR follow-
ing the year-1 biomarker addition.
Results
Table 1 shows some characteristics of contributing cases
and controls, separately for CHD and stroke, and separ-
ately for the E-alone and E+ P trials. Compared to E+ P
trial women, E-alone trial women tended to have higher
BMI, and to be more likely to have used postmenopausal
hormones prior to trial enrollment.
Table 2 shows geometric means and 95% confidence
intervals (CIs) for each selected analyte at baseline, for
cases and controls separately, along with P values for
their comparison. P values for testing equality of case-
control differences between the two trials are also
shown, and no between-trial differences were suggested.
Combined trial comparisons show CHD case-control
differences (P <0.05) for B2M and CFD, and stroke case-
control differences for B2M and IGFBP4.
Case-control comparisons based on blood drawn at 1
year following randomization (year 1) are also shown in
Table 2, excluding cases occurring in the first year of
trial participation. For B2M, combined trial case-control
differences at 1 year were evident for both CHD and
stroke; and for IGFBP4, were evident for stroke.
More refined baseline analyte comparisons, using lo-
gistic regression, are shown in Table 3. These use all
cases and controls for each disease, include indicator
variables for treatment (active vs. placebo) and trial (E +
P vs. E-alone), all control matching variables, and several
other CVD risk factors (listed above). The ORs shown
are for a 30% increment in the proteomic marker, a
value well within the observed range of values for the
biomarkers studied. These logistic regression analyses
demonstrate positive associations of B2M and CFD, a
modest inverse association of THBS1, and a possible
positive association of IGFBP1 with CHD risk, each of
which concurs in direction with the preceding proteomic
discovery results. These analyses also imply positive
associations of stroke risk with IGFBP2, IGFBP4, and
B2M. Disease risk did not differ between the two trial
cohorts, after controlling for the listed factors.
We previously reported [17] positive associations of
baseline B2M with CHD risk and baseline IGFBP4 with
stroke risk during the first year from randomization in
the WHI HT trials. With the longer-term data analyzed
here the estimated CHD OR (95% CI) for a 30% incre-
ment in baseline B2M is 1.28 (1.08, 2.54) following year
1, and the stroke OR (95% CI) for a 30% increment in
baseline IGFBP4 is 1.16 (1.03, 1.30) following year 1.
These are similar to the ORs for the first year [17], and
for the overall time period as shown in Table 3.
Additional analyses (not shown) examined ORs for a
30% increase in baseline biomarker, separately in the pla-
cebo and treatment groups for each clinical trial.
The B2M associations with risk were evident in both
placebo and treatment groups for both diseases. The
CFD associations with CHD were primarily evident in
the active treatment groups in both trials; whereas the
IGFBP4 association with stroke was most evident in the
placebo groups for both trials.
There were some noteworthy correlations among the
protein concentrations considered for each disease. For
CHD, baseline and year 1 B2M concentrations corre-
lated positively with corresponding CFD concentrations
in both the placebo and active hormone groups, in both
the E-alone and E +P trials. For stroke, positive correla-
tions of B2M with each of IGFBP2, IGFBP4, and IGFBP6
were also evident at baseline and year 1 in both treat-
ment groups, and both trials. Table 4 shows ORs for the
five analytes jointly, for each disease, in analyses that
otherwise include the same regression variables as
Table 3. The strongest associations in these analyses are
for B2M and CHD and for IGFBP4 and stroke, while an
inverse association of CHD risk with THBS1 and a posi-
tive association of stroke risk with IGFBP2 are also
observed.
In Table 5, the year-1 protein concentrations are in-
cluded in analyses like those in Table 3, but based on
cases occurring after year 1 and their disease-specific
controls. Estimated ORs are shown for a 30% increment
in baseline analyte, and for a 30% increment in the ratio
of year 1 to baseline concentration (that is, 30%
‘change’). Toward assessing mediation of HT effects,
treatment ORs are shown with only baseline biomarkers
included in the analysis, along with corresponding ORs
when the analyte change is added to the OR model. For
CHD, the treatment OR was essentially unchanged when
B2M change was added to the analysis, though there
was a suggestion of higher risk (OR of 1.13) among
women having a positive concentration change. Interest-
ingly, even though evidence for an association of base-
line IGFBP1 with CHD risk was weak, there was a
nearly significant association (P =0.06) of risk with
change from baseline to year 1 in IGFBP1 concentration,
and the OR for treatment was null (OR =0.96) after con-
trolling for IGFBP1 change.
For stroke, baseline to 1 year B2M change was posi-
tively associated with risk, though the treatment OR was
not affected by including B2M change in the analysis.
Similarly, OR for treatment was little altered when
changes in any of the IGF binding proteins or HPX was
added to the analytic model.
Prentice et al. Genome Medicine 2013, 5:112 Page 4 of 15
http://genomemedicine.com/content/5/12/112Table 1 Characteristics of CHD cases and controls and stroke cases and controls from the WHI postmenopausal HT
trials of estrogen plus progestin (E+ P) and estrogen-alone (E-alone): Mean±SE for continuous baseline covariates,
N (%) for categorical baseline covariates
CHD
E+P E-alone
Cases Controls P value
a Cases Controls P value
a
N 206 202 152 150
Age
b (years) 66.61 (7.55) 66.49 (7.44) 0.87 67.55 (6.01) 67.58 (6.03) 0.96
BMI (kg/m
2) 28.81 (5.61) 27.57 (5.38) 0.02 30.21 (5.71) 29.49 (5.86) 0.28
Systolic BP (mmHg) 135.04 (18.62) 130.32 (17.85) 0.01 138.48 (18.50) 129.75 (17.77) <.0001
Diastolic BP (mmHg) 77.04 (10.26) 75.39 (8.83) 0.08 76.29 (10.81) 74.56 (8.81) 0.13
Race (%) 0.77 0.66
White 185 (91.6) 180 (89.6) 117 (78.0) 118 (79.2)
Black 11 (5.4) 13 (6.5) 26 (17.3) 27 (18.1)
Other 3 (3.0) 8 (4.0) 7 (4.7) 4 (2.7)
Smoking (%) 0.001 0.11
Never 92 (46.0) 114 (57.0) 70 (46.7) 79 (53.4)
Past 68 (34.0) 72 (36.0) 55 (36.7) 56 (37.8)
Current 40 (20.0) 14 (7.0) 25 (16.7) 13 (8.8)
History of CHD
b (%) 1 1
Yes 19 (9.2) 19 (9.4) 21 (13.8) 21 (14.0)
No 187 (90.8) 183 (90.6) 131 (86.2) 129 (86.0)
Treated diabetes (%) 0.04 0.0003
Yes 29 (14.1) 15 (7.4) 39 (25.7) 14 (9.3)
No 177 (85.9) 187 (92.6) 113 (74.3) 136 (90.7)
Prior use of HT (%) 0.04 0.13
Never 152 (73.8) 152 (75.2) 96 (63.2) 97 (64.7)
Past 48 (23.3) 39 (19.3) 48 (31.6) 37 (24.7)
Current 6 (2.9) 11 (5.4) 8 (5.3) 16 (10.7)
Stroke
E+P E-alone
Cases Controls P value
a Cases Controls P value
a
N 182 176 180 170
Age
b (years) 67.90 (6.61) 67.86 (6.61) 0.96 67.56 (6.34) 67.43 (6.49) 0.85
BMI (kg/m
2) 28.04 (4.94) 27.81 (6.26) 0.70 29.66 (5.42) 28.55 (5.39) 0.06
Systolic BP (mmHg) 137.82 (19.79) 128.24 (15.20) <.0001 139.93 (19.34) 132.87 (17.51) 0.0004
Diastolic BP (mmHg) 76.73 (10.43) 73.93 (9.35) 0.008 77.99 (9.29) 76.45 (9.21) 0.12
Race (%) 0.68 0.98
White 156 (87.6) 156 (90.2) 134 (74.4) 126 (75.4)
Black 14 (7.9) 12 (6.9) 30 (16.7) 27 (16.2)
Other 8 (4.5) 5 (2.9) 16 (8.9) 14 (8.4)
Smoking (%) 0.002 0.98
Never 77 (42.5) 102 (59.3) 92 (52.9) 60 (53.9)
Past 74 (40.9) 58 (33.7) 68 (39.1) 64 (38.3)
Current 30 (16.6) 12 (7.0) 14 (8.0) 13 (7.8)
History of stroke
b (%) 1 1
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effect mediation by each of these proteins when allowing
for technical measurement error in protein assessment,
with the blind duplicate data used to estimate the meas-
urement error variance for the (log-transformed) protein
concentrations. The treatment ORs were little changed
from Table 5 after making this measurement error cor-
rection. For example, the treatment effect OR (95% CI),
in analyses that include measurement error corrected
baseline and 1-year IGFBP1 values, was 0.89 (0.54, 1.45).
Other work (also not shown) repeated the Table 5 analyses
with cases and controls restricted to women who adhered
to their assigned medications during the first year of HT
trial participation (at least 80% of pills taken), with little
change in HT mediation findings. Further analyses repeated
Table 3 excluding women who were being treated for dia-
b e t e sa tb a s e l i n e( T a b l e1 )w i t hv e r yl i t t l ec h a n g ei nt h e
ORs for the proteomic markers.
Discussion
Table 6 presents correlations of each of the proteomic
markers with plasma measures of lipids, inflammatory
factors, and thrombotic factors, as well as insulin, glu-
cose, white blood cell count, and blood pressure, to fa-
cilitate the integration of the associations just described
with knowledge about CHD and stroke pathogenesis.
These measures were available [18,19] at baseline and 1
year, for all cases and controls, except the 100 stroke
case-control pairs that were added late to the case-control
study. All variables were log-transformed in calculating
these correlations (95% CIs). The correlations shown in
Table 6, and ORs for a 30% increment in the proteomic
marker from analyses like those shown in Table 3, but with
each of the variables on the left side of Table 6 included in
the logistic regression model, will be described below for
each of the proteomic markers in turn.
This study confirms plasma B2M to be a risk marker
for both CHD and stroke, over an average follow-up
period of about 4 years for CHD, and longer for stroke.
B2M is an amyloidogenic protein that is elevated in
hemodialysis patients [26,27], and has been reported to
be positively associated with CVD risk factors [28] and
with CVD events among patients having chronic kidney
disease [29], asymptomatic carotid atherosclerosis [30],
or peripheral arterial disease in a healthy elderly popula-
tion [31]. B2M was found to be increased by about 15%
by both types of HT both in the control groups studied
here and in our preceding proteomics discovery research
[23,24].
From Table 6 it can be seen that B2M has a moderate
inverse correlation with HDL-cholesterol, and moderate
positive correlations with coagulation factors FVIII and
vWF, and with insulin and diastolic blood pressure in
this population of postmenopausal women. When the
Table 6 variables were added (left side) to the regression
model, the OR (95% CI) for a 30% increment in B2M
was 1.21 (1.06, 1.37) for CHD, in close proximity to that
shown in Table 3 without the addition of these variables,
and was 1.46 (1.21, 1.78) for stroke, noticeably stronger
than that given in Table 3.
While baseline B2M relates rather clearly to the risk of
both CHD and stroke (Table 3), when baseline to 1
year B2M change was added to the regression model
(Table 5), it was B2M change that conveyed the greater
disease risk, especially for stroke. Recent B2M change
deserves consideration as a stroke and possibly a CHD
risk marker. However, the HT treatment OR estimates
changed little when the B2M change was added to the
regression model. Evidently, B2M change is not corre-
lated strongly enough with randomization assignment in
the WHI trials for evidence of important mediation of
HT effects on these diseases to emerge.
Table 1 Characteristics of CHD cases and controls and stroke cases and controls from the WHI postmenopausal HT
trials of estrogen plus progestin (E+ P) and estrogen-alone (E-alone): Mean±SE for continuous baseline covariates,
N (%) for categorical baseline covariates (Continued)
Yes 5 (2.7) 4 (2.3) 9 (5.0) 9 (5.3)
No 177 (97.3) 172 (97.7) 171 (95.0) 161 (94.7)
Treated diabetes (%) 0.005 0.05
Yes 20 (11.0) 5 (2.8) 28 (15.6) 14 (8.2)
No 162 (89.0) 171 (97.2) 152 (84.4) 156 (91.8)
Prior use of HT (%) 0.50 0.40
Never 135 (74.2) 129 (73.3) 92 (51.1) 87 (51.2)
Past 42 (23.1) 38 (21.6) 75 (41.7) 64 (37.6)
Current 5 (2.7) 9 (5.1) 13 (7.2) 19 (11.2)
aP value from chi-square test.
bCase-control matching variables.
BMI, body mass index; BP, blood pressure.
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WHI postmenopausal HT trials of estrogen plus progestin (E+ P) and estrogen-alone (E-alone)
CHD
E+P E-alone Difference between cohorts
b Overall case vs. control difference
c
Cases Controls P value
a Cases Controls P value
a
N 206 202 152 150
B2M (mg/mL) N=206, 141
d N= 202, 138
d N =152, 110
d N=150, 108
d
Baseline 0.13 (0.06, 0.29) 0.11 (0.06, 0.22) <.001 0.13 (0.06, 0.32) 0.12 (0.05, 0.27) 0.05 0.44 0.0001
Year 1 0.15 (0.07, 0.31) 0.13 (0.06, 0.27) 0.01 0.15 (0.06, 0.38) 0.14 (0.07, 0.30) 0.04 0.87 0.003
Change 1.04 (0.51, 2.11) 1.03 (0.55, 1.94) 0.68 1.02 (0.48, 2.17) 1.00 (0.60, 1.67) 0.18 0.69 0.67
ORM1 (mg/mL) N=204, 139 N= 202, 138 N =133, 96 N=150, 108
Baseline 0.52 (0.27, 1.02) 0.49 (0.27, 0.91) 0.10 0.52 (0.25, 1.08) 0.51 (0.25, 1.02) 0.61 0.52 0.16
Year 1 0.47 (0.24, 0.91) 0.46 (0.22, 0.94) 0.66 0.49 (0.25, 0.96) 0.47 (0.2, 1.08) 0.95 0.97 0.32
Change 0.93 (0.50, 1.71) 0.93 (0.48, 1.78) 0.85 0.93 (0.48, 1.79) 0.91 (0.51, 1.63) 0.41 0.68 0.75
THBS1 (ug/mL) N=172, 125 N= 175, 124 N =145, 106 N=108, 108
Baseline 1.98 (0.18, 21.35) 2.10 (0.19, 23.82) 0.44 1.85 (0.24, 14.36) 2.36 (0.24, 23.08) 0.02 0.35 0.14
Year 1 1.98 (0.2, 19.12) 2.16 (0.19, 24.55) 0.27 2.16 (0.27, 17.14) 2.39 (0.25, 23) 0.10 0.95 0.38
Change 0.96 (0.12, 7.96) 0.94 (0.13, 6.67) 0.17 1.24 (0.16, 9.53) 0.97 (0.16, 5.76) 0.08 0.26 0.25
CFD (ug/mL) N=204, 139 N= 202, 138 N =150, 108 N=131, 91
Baseline 0.79 (0.35, 1.74) 0.72 (0.37, 1.4) 0.003 0.78 (0.36, 1.67) 0.76 (0.4, 1.45) 0.22 0.27 0.02
Year 1 0.75 (0.32, 1.73) 0.7 (0.34, 1.42) 0.05 0.81 (0.33, 1.98) 0.77 (0.36, 1.65) 0.20 0.75 0.09
Change 0.98 (0.58, 1.65) 0.96 (0.65, 1.43) 0.26 1.04 (0.63, 1.70) 1.01 (0.72, 1.44) 0.22 0.95 0.30
IGFBP1 (ng/mL) N=201, 139 N= 201, 138 N =150, 108 N=145, 105
Baseline 10.98 (1.56, 77.48) 10.71 (1.26, 90.8) 0.77 9.21 (1.09, 77.72) 7.61 (0.75, 76.76) 0.19 0.32 0.25
Year 1 15.70 (1.85, 133.37) 15.62 (1.81, 134.43) 0.85 17.67 (1.49, 209.42) 12.52 (0.91, 172.68) 0.06 0.12 0.16
Change 1.63 (0.33, 8.20) 1.40 (0.24, 8.15) 0.41 1.79 (0.37, 8.52) 1.87 (0.27, 12.83) 0.13 0.21 0.38
Stroke
E+P E-alone Difference between cohorts
b Overall case vs. control difference
c
Cases Controls P value
a Cases Controls P value
a
N 182 176 180 170
B2M (mg/mL) N=181, 146
d N= 174, 146
d N =179, 141
d N=170, 134
d
Baseline 0.12 (0.04, 0.38) 0.11 (0.06, 0.20) 0.02 0.13 (0.06, 0.25) 0.11 (0.06, 0.22) 0.002 0.18 0.003
Year 1 0.12 (0.06, 0.26) 0.11 (0.06, 0.21) 0.03 0.13 (0.06, 0.27) 0.12 (0.06, 0.24) 0.06 0.84 0.001
Change 1.05 (0.33, 3.32) 0.99 (0.69, 1.40) 0.32 1.03 (0.64, 1.65) 1.04 (0.70, 1.56) 0.99 0.20 0.31
IGFBP2 (ng/mL) N=171, 136 N= 169, 139 N =164, 128 N=158, 125
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2Table 2 Geometric mean and 95% CI for baseline and year-1 biomarker values and for the year 1 to baseline ratio (change) for cases and controls from the
WHI postmenopausal HT trials of estrogen plus progestin (E+ P) and estrogen-alone (E-alone) (Continued)
Baseline 80.9 (23.63, 276.99) 73.52 (15.27, 353.91) 0.53 72.55 (16.63, 316.48) 67.38 (15.28, 297.04) 0.36 0.85 0.14
Year 1 64.95 (16.88, 249.86) 66.11 (17.02, 256.78) 0.65 60.57 (12.3, 298.34) 57.99 (12.4, 271.3) 0.63 0.64 0.86
Change 0.85 (0.33, 2.17) 0.90 (0.40, 2.04) 0.42 0.86 (0.34, 2.17) 0.91 (0.32, 2.55) 0.15 0.96 0.16
IGFBP4 (ug/mL) N=175, 139 N= 170, 139 N =168, 131 N=164, 128
Baseline 0.49 (0.22, 1.08) 0.45 (0.18, 1.09) 0.11 0.48 (0.21, 1.11) 0.43 (0.20, 0.95) 0.03 0.87 0.004
Year 1 0.56 (0.24, 1.35) 0.52 (0.23, 1.16) 0.05 0.57 (0.24, 1.39) 0.5 (0.21, 1.18) 0.01 0.47 0.003
Change 1.05 (0.54, 2.05) 1.05 (0.53, 2.10) 0.76 1.10 (0.59, 2.07) 1.03 (0.55, 1.93) 0.08 0.24 0.59
IGFBP6 (ug/mL) N=166, 130 N= 159, 133 N =161, 126 N=153, 118
Baseline 0.15 (0.05, 0.43) 0.14 (0.05, 0.4) 0.56 0.15 (0.04, 0.47) 0.14 (0.04, 0.55) 0.99 0.89 0.55
Year 1 0.14 (0.05, 0.41) 0.13 (0.03, 0.51) 0.53 0.14 (0.04, 0.47) 0.14 (0.03, 0.59) 0.58 0.42 0.60
Change 0.92 (0.31, 2.75) 0.91 (0.25, 3.38) 0.99 0.96 (0.28, 3.31) 0.93 (0.33, 2.61) 0.50 0.86 0.57
HPX (mg/mL) N=175, 140 N= 170, 140 N =169, 131 N=164, 128
Baseline 0.55 (0.33, 0.92) 0.54 (0.31, 0.95) 0.93 0.57 (0.31, 1.06) 0.54 (0.31, 0.97) 0.17 0.42 0.19
Year 1 0.52 (0.33, 0.82) 0.52 (0.31, 0.87) 0.95 0.54 (0.32, 0.9) 0.53 (0.33, 0.83) 0.35 0.78 0.42
Change 1.00 (0.64, 1.58) 0.99 (0.64, 1.51) 0.50 1.02 (0.67, 1.55) 1.04 (0.71, 1.52) 0.71 0.38 0.09
aP value from t-test for log-transformed biomarker values.
bFor the P value between cohorts, a linear regression of log-biomarker value on trial, case versus control status and their interaction was fitted. The reported P value is the P value of the interaction.
cFor the P value of overall difference between cases and controls, a linear regression of log-biomarker value on trial and case versus control status was fitted. The reported P value is the P value of the case versus
control variable.
dNumber of women at baseline and 1 year, respectively.
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2The Table 3 analyses also suggest CFD (adipsin) to be
a CHD risk marker, although its association with CHD
risk is not significant in analyses that include B2M and
the other CHD risk marker candidates (Table 4). CFD
correlates inversely with HDL-cholesterol and positively
with vWF, insulin, glucose, and diastolic blood pressure.
When the Table 6 variables are added to the regression
model, the CHD OR (95% CI) for a 30% increment in
CFD becomes a non-significant 1.11 (0.96, 1.29). CFD is
secreted by adipocytes into the bloodstream. Such adipo-
cytes have been reported to impact multiple functions
(blood pressure, lipid metabolism, and hemostasis) to be
linked to CVD [32] and to be elevated among obese per-
sons. There is a suggestion (Table 5) that CFD change
may relate positively to CHD risk, but the association is
not significant.
IGF1 and IGFBP1 have been found to associate posi-
tively with all cause and ischemic heart disease mortality
in the elderly Rancho Bernardo cohort [33]. Here, baseline
IGFBP1 was positively correlated with HDL-cholesterol
and inversely associated with glucose. After including
these and the other Table 6 measures in the regression
analysis, the CHD OR (95% CI) for a 30% IGFBP1 incre-
ment was 1.08 (1.02, 1.14). Also, the IGFBP1 change from
baseline to year 1 was nearly significant (P=0.06; Table 5)
in its association with disease risk. Moreover, the HT
treatment OR was reduced to a null value (0.96) after
allowing for the IGFBP1 change. Hence, IGFBP1 deserves
consideration among biomarkers that may help to explain
HT effects on CHD. This mediation possibility may be
dampened, however, by the suggestively larger IGFBP1
changes with E-alone versus E+P [24], whereas CHD ORs
were somewhat larger for E+P [11] than for E-alone [12].
The HT regimes studied here are taken orally, and
the first-pass hepatic metabolism is known to stimu-
late a wide variety of proteins. IGFBP1 is recognized as
a liver-selective protein [34], so that this protein may
be unaffected by transdermal estrogens, that are being
Table 3 ORs (95% CIs) for a 30% baseline biomarker increment from analyses that include data from both WHI
postmenopausal HT trials
CHD
B2M ORM1 THBS1 CFD IGFBP1
Baseline biomarker 1.21 (1.09, 1.35)
a,c 1.01 (0.89, 1.14) 0.97 (0.93, 1.00) 1.16 (1.03, 1.31)
c 1.03 (0.99, 1.08)
Treatment
b 1.32 (0.97, 1.81) 1.33 (0.97, 1.81) 1.34 (0.96, 1.87) 1.31 (0.95, 1.78) 1.29 (0.94, 1.77)
Trial
b 1.13 (0.82, 1.56) 1.09 (0.79, 1.51) 1.02 (0.72, 1.44) 1.09 (0.79, 1.50) 1.05 (0.76, 1.47)
Stroke
B2M IGFBP2 IGFBP4 IGFBP6 HPX
Baseline biomarker 1.18 (1.04, 1.34)
a,c 1.10 (1.03, 1.18)
c 1.16 (1.04, 1.28)
c 1.01 (0.94, 1.09) 1.10 (0.95, 1.27)
Treatment
b 1.90 (1.38, 2.62) 1.77 (1.27, 2.46) 1.76 (1.21, 2.54) 1.70 (1.22, 2.38) 1.79 (1.30, 2.48)
Trial
b 1.09 (0.79, 1.50) 1.10 (0.79, 1.53) 1.09 (0.75, 1.59) 1.11 (0.79, 1.55) 1.13 (0.81, 1.56)
aAll analyses also include baseline age, prior history of study disease, systolic and diastolic blood pressure, smoking history, treated diabetes history, prior HT use,
and body mass index as regression variables to control confounding.
bTreatment, 1 - active; 0 - placebo; Trial, 1 - E+ P trial (no hysterectomy), 0 - E-alone trial (post-hysterectomy).
cSignificant at P= 0.05.
Table 4 ORs (95% CIs) for a 30% baseline biomarker increment, from analyses that combine trials and treatment arms
in the WHI postmenopausal HT trials, with biomarkers simultaneously modeled
Baseline biomarker CHD
a Baseline biomarker Stroke
a
B2M 1.19 (1.05, 1.35)
b,c B2M 1.11 (0.96, 1.29)
b
ORM1 1.06 (0.93, 1.22) IGFBP2 1.08 (1.00, 1.17)
c
THBS1 0.96 (0.92, 0.99)
c IGFBP4 1.17 (1.04, 1.32)
c
CFD 1.09 (0.93, 1.28) IGFBP6 0.97 (0.89, 1.05)
IGFBP1 1.01 (0.96, 1.06) HPX 1.08 (0.92, 1.26)
Treatment
d 1.28 (0.91, 1.82) Treatment
b 1.71 (1.21, 2.42)
Trial
d 1.00 (0.70, 1.44) Trial
b 1.08 (0.76, 1.53)
aCHD analyses based on 596 combined cases and controls; stroke analyses based on 620 combined cases and controls.
bAll analyses include baseline age, prior history of study disease, systolic and diastolic blood pressure, smoking history, treated diabetes history, prior HT use, and
body mass index as regression variables to control confounding.
cSignificant at P= 0.05.
dTreatment, 1 - active; 0 - placebo; Trial, 1 - E+ P trial (no hysterectomy), 0 - E-alone trial (post-hysterectomy).
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http://genomemedicine.com/content/5/12/112increasingly used in clinical practice to treat menopausal
symptoms, since these bypass the liver.
THBS1 has a modest inverse association with CHD
risk, consistent with our discovery work [17]. This pro-
tein has little correlation with the Table 6 factors, though
there is some positive association with systolic blood
pressure. The OR (95% CI) for a 30% increment in
THBS1 is 0.95 (0.91, 1.00) after including all measures
on the left side of Table 6 in the analysis. Thrombin, an
important factor in relation to inflammation, coagula-
tion, and wound healing, has been shown to regulate
THBS1 expression in endothelial cells [35].
The analyses presented here provide little support for
ORM1 as a risk marker for CHD among postmeno-
pausal women. It relates inversely to HDL-cholesterol,
and positively to IL-6 and MMP-9, D-dimer, vWF, and
glucose. When the Table 6 variables are included in the
regression analysis, the OR (95% CI) for a 30% incre-
ment in ORM1 is 0.84 (0.77, 1.00), suggesting a possible
weak inverse incremental association.
There is an extensive literature, reviewed in [36], on
the key role of the insulin-like growth factor system in
central nervous system development, function, and re-
pair in animal models. The six IGFBPs coordinate and
regulate the biologic activity of IGF1 and IGF2. In spite
of sequence homology, the IGFBPs may have quite dif-
ferent biological activity, due to differing abundances,
with IGFBP-2, -4, and -5 predominating in the brain,
and due to post-translational modifications [36,37]. Also,
IGF1 and IGF2 levels have been found to associate
inversely with ischemic stroke risk in a Danish case-
control study [38], and also with stroke outcome in
human studies [39,40].
Here, our validation exercises confirm a positive asso-
ciation of plasma IGFBP2 and IGFBP4 with stroke risk
among postmenopausal women. An association was not
confirmed for IGFBP6, which has low abundance in the
brain in animal models [36,37]. From Table 6 one sees
that baseline IGFBP4 and IGFBP6 have quite similar
Table 5 ORs (95% CIs) for a 30% increment in baseline
biomarker, and in year 1 to baseline biomarker ratio
(change), based on cases occurring after year 1 and
disease-specific controls, from the WHI estrogen plus
progestin and estrogen-alone HT trials
CHD
Modeled variables N
a Biomarker values included
Baseline only Baseline+change
Treatment
a 491 1.14 (0.79, 1.66)
b 1.16 (0.80, 1.68)
B2M baseline 1.22 (1.06, 1.40) 1.13 (0.95, 1.34)
B2M change 1.12 (0.96, 1.32)
Trial
a 1.09 (0.74, 1.59) 1.08 (0.74, 1.59)
Treatment
a 489 1.21 (0.83, 1.75)
b 1.24 (0.83, 1.84)
ORM1 baseline 1.00 (0.87, 1.16) 0.98 (0.82, 1.18)
ORM1 change 1.03 (0.87, 1.24)
Trial
a 1.03 (0.71, 1.51) 1.03 (0.71, 1.51)
Treatment
a 395 1.11 (0.73, 1.68)
b 1.11 (0.73, 1.68)
THBS1 baseline 0.95 (0.91, 1.00) 0.95 (0.89, 1.01)
THBS1 change 1.01 (0.95, 1.07)
Trial
a 0.96 (0.66, 1.39) 0.92 (0.60, 1.41)
Treatment
a 489 1.19 (0.82, 1.72)
b 1.26 (0.86 1.85)
CFD baseline 1.09 (0.95, 1.24) 0.93 (0.73 1.19)
CFD change 1.20 (0.94 1.52)
Trial
a 1.03 (0.73, 1.46) 1.06 (0.72 1.56)
Treatment
a 479 1.18 (0.81, 1.72)
b 0.96 (0.62, 1.49)
IGFBP1 baseline 1.01 (0.96, 1.06) 0.97 (0.90, 1.03)
IGFBP1 change 1.07 (0.99, 1.14)
Trial
a 0.98 (0.67, 1.44) 1.01 (0.69, 1.50)
Stroke
Modeled variables N
a Biomarker values included
Baseline only Baseline+change
Treatment
a 552 1.84 (1.28, 2.64)
b 1.87 (1.30, 2.70)
B2M baseline 1.10 (0.97, 1.23) 0.99 (0.86, 1.14)
B2M change 1.24 (1.03, 1.50)
Trial
a 1.10 (0.76, 1.59) 1.13 (0.78, 1.64)
Treatment
a 508 1.67 (1.14, 2.44)
b 1.57 (1.05, 2.33)
IGFBP2 baseline 1.09 (1.00, 1.18) 1.14 (1.00, 1.31)
IGFBP2 change 0.94 (0.84, 1.06)
Trial
a 1.09 (0.74, 1.60) 1.10 (0.75, 1.61)
Treatment
a 524 1.77 (1.22, 2.57)
b 1.74 (1.20, 2.53)
IGFBP4 baseline 1.18 (1.04, 1.34) 1.10 (0.93, 1.30)
IGFBP4 change 1.10 (0.94, 1.28)
Trial
a 1.08 (0.75, 1.30) 1.10 (0.75, 1.61)
Treatment
a 474 1.60 (1.08, 2.37)
b 1.60 (1.08, 2.37)
IGFBP6 baseline 0.99 (0.90, 1.09) 0.99 (0.89, 1.11)
IGFBP6 change 0.99 (0.91, 1.09,)
Trial
a 1.12 (0.75, 1.66) 1.11 (0.75, 1.66)
Table 5 ORs (95% CIs) for a 30% increment in baseline
biomarker, and in year 1 to baseline biomarker ratio
(change), based on cases occurring after year 1 and
disease-specific controls, from the WHI estrogen plus
progestin and estrogen-alone HT trials (Continued)
Treatment
a 526 1.74 (1.20, 2.51)
b 1.74 (1.20, 2.51)
HPX baseline 1.06 (0.88, 1.28) 1.07 (0.84, 1.36)
HPX change 0.99 (0.77, 1.29)
Trial
a 1.11 (0.76, 1.62) 1.11 (0.76, 1.62)
aN, total number of cases plus controls; Treatment, 1 - active; 0 - placebo; Trial,
1 - E+ P trial (no hysterectomy), 0 - E-alone trial (post-hysterectomy).
bAll analyses include baseline age, prior history of study disease, systolic and
diastolic blood pressure, smoking history, treated diabetes history, prior HT
use, and body mass index as regression variables to control confounding.
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http://genomemedicine.com/content/5/12/112Table 6 Pearson correlation (bolded) and 95% CIs for baseline log-transformed proteomic markers and baseline log-transformed variables involved in CHD
and stroke pathophysiology
CHD and stroke risk factors Proteomic marker
B2M ORM1 THBS1 CFD IGFBP1 IGFBP2 IGFBP4 IGFBP6 HPX
Lipids
HDL-C -0.16 -0.23 -0.10 -0.25 0.22 0.52 -0.25 -0.18 -0.21
(-0.27, -0.05) (-0.36, -0.09) (-0.24, 0.06) (-0.38, -0.11) (0.08, 0.36) (0.37, 0.64) (-0.41, -0.07) (-0.36, 0.01) (-0.38, -0.03)
LDL-C -0.04 0.04 0.09 -0.01 -0.05 -0.15 0.01 0.02 0.14
(-0.15, 0.08) (-0.10, 0.19) (-0.06, 0.24) (-0.16, 0.13) (-0.19, 0.10) (-0.32, 0.04) (-0.18, 0.19) (-0.17, 0.21) (-0.04, 0.32)
Inflammatory markers
CRP -0.04 0.02 0.12 -0.04 0.05 -0.11 -0.02 -0.04 0.13
(-0.15, 0.08) (-0.12, 0.17) (-0.03, 0.27) (-0.18, 0.11) (-0.10, 0.19) (-0.28, 0.08) (-0.21, 0.16) (-0.23, 0.15) (-0.06, 0.30)
IL-6 0.09 0.30 0.09 0.05 −0.11 −0.16 0.30 0.21 0.23
(-0.03, 0.20) (0.16, 0.43) (-0.07, 0.24) (-0.10, 0.20) (-0.25, 0.04) (-0.34, 0.03) (0.12, 0.46) (0.01, 0.39) (0.05, 0.40)
MMP-9 0.08 0.30 -0.06 0.11 -0.06 -0.20 0.06 0.09 0.07
(-0.03, 0.20) (0.16, 0.43) (-0.21, 0.10) (-0.03, 0.26) (-0.20, 0.09) (-0.37, -0.01) (-0.12, 0.24) (-0.11, 0.27) (-0.11, 0.25)
Thrombosis and other blood markers
Factor VIII 0.21 0.14 0.06 -0.02 0.08 -0.11 0.23 0.19 0.12
(0.10, 0.32) (0.00, 0.28) (-0.10, 0.21) (-0.16, 0.12) (-0.07, 0.22) (-0.29, 0.08) (0.05, 0.39) (0.00, 0.37) (-0.06, 0.30)
Factor 1.2 0.01 -0.04 -0.02 0.08 0.09 0.06 -0.02 0.06 0.31
(-0.10, 0.13) (-0.18, 0.10) (-0.18, 0.13) (-0.07, 0.22) (-0.06, 0.23) (-0.13, 0.24) (-0.20, 0.16) (-0.13, 0.25) (0.14, 0.47)
D-Dimer -0.02 0.15 -0.10 0.08 0.11 -0.04 0.00 0.00 0.15
(-0.14, 0.10) (0.00, 0.29) (-0.26, 0.06) (-0.07, 0.23) (-0.04, 0.26) (-0.23, 0.15) (-0.19, 0.18) (-0.19, 0.20) (-0.04, 0.32)
vWF 0.13 0.22 0.08 0.36 -0.01 0.15 0.18 0.09 0.06
(0.02, 0.24) (0.07, 0.35) (-0.22, 0.08) (0.23, 0.48) (-0.16, 0.13) (-0.03, 0.33) (0.00, 0.35) (-0.10, 0.28) (-0.13, 0.24)
Insulin 0.23 -0.03 -0.01 0.19 -0.04 0.02 0.29 0.23 0.04
(0.12, 0.33) (-0.17, 0.11) (-0.16, 0.14) (0.05, 0.32) (-0.18, 0.11) (-0.16, 0.21) (0.11, 0.44) (0.04, 0.40) (-0.14, 0.22)
Glucose 0.03 0.17 0.02 0.24 -0.44 -0.13 0.29 0.28 0.26
(-0.08, 0.15) (0.02, 0.31) (-0.14, 0.17) (0.10, 0.38) (-0.55, -0.31) (-0.31, 0.07) (0.10, 0.45) (0.08, 0.45) (0.07, 0.43)
WBC 0.01 0.02 0.06 0.02 -0.10 -0.30 0.09 0.21 0.11
(-0.10, 0.12) (-0.12, 0.17) (-0.09, 0.21) (-0.12, 0.16) (-0.24, 0.04) (-0.46, -0.12) (-0.10, 0.27) (0.02, 0.39) (-0.08, 0.29)
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2Table 6 Pearson correlation (bolded) and 95% CIs for baseline log-transformed proteomic markers and baseline log-transformed variables involved in CHD
and stroke pathophysiology (Continued)
Blood pressure
Systolic BP 0.08 0.10 0.17 0.04 -0.03 -0.25 0.00 0.17 0.14
(-0.04, 0.19) (-0.04, 0.24) (0.02, 0.32) (-0.11, 0.18) (-0.17, 0.12) (-0.42, -0.07) (-0.18, 0.18) (-0.02, 0.35) (-0.04, 0.31)
Diastolic BP 0.18 0.08 -0.11 0.19 0.00 -0.06 0.18 0.18 0.05
(0.08, 0.28) (-0.06, 0.22) (-0.25, 0.05) (0.05, 0.32) (-0.15, 0.14) (-0.21, 0.09) (0.03, 0.32) (0.03, 0.33) (-0.10, 0.19)
Correlations are based on data from 357 controls drawn from the placebo groups of the WHI postmenopausal HT trials of estrogen plus progestin and estrogen-alone. Estimated correlations are bolded for ease
of viewing.
BP: blood pressure; CRP: C-reactive protein; Factor 1.2: prothrombin fragment 1.2; Factor VIII: clotting factor eight; HDL-C: high-density lipoprotein cholesterol; IL-6: interleukin 6; LDL-C: low-density lipoprotein cholesterol;
MMP-9: matrix metallaprotinase-9; vWF: von villebrand factor; WBC: total leukocyte count; WHI: Women’s Health Initiative.
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2correlation patterns with cardiovascular risk biomarkers,
with a negative correlation with HDL-cholesterol and
positive correlation with IL-6, MMP-9, Factor VIII, insu-
lin, glucose, and diastolic blood pressure. These patterns
are also very similar to those for B2M. In contrast,
IGFBP2 has a fairly strong positive correlation with
HDL-cholesterol, and negative correlations with MMP-
9, WBC, and systolic blood pressure. When the Table 6
variables are included in the analysis, the OR (95% CI)
for a 30% increment in IGFBP2 is 1.21 (1.08, 1.35), larger
than that given in Table 3, while corresponding ORs
(95% CIs) are 1.14 (0.99, 1.32) for IGFBP4 and 1.06
(0.95, 1.17) for IGFBP6. In conjunction with Table 4, one
can infer that IGFBP4 and IGFBP2 are associated with
stroke risk beyond that attributable to the established
biomarkers considered here, while there is little evidence
for further association with IGFBP6. However, there was
limited evidence of important mediation of HT effects
on stroke by either IGFBP4 or IGFBP2, and only a weak
suggestion of a positive association between IGFBP4
change from baseline to year 1 and stroke risk.
Hemopexin had been shown in mice to be neuropro-
tective through high-affinity binding of the pre-oxidant
free heme [41]. The baseline HPX measures obtained
here correlated negatively with HDL-cholesterol and
positively with IL-6, Factor 1.2, and glucose, and the OR
(95% CI) for a 30% increment in HPX was 1.05 (0.87,
1.28) after including each of the Table 6 variables in the
analysis. Overall, neither baseline nor change in HPX
was related to stroke risk in these analyses, but this
could be due to the poor reliability of the HPX ELISA
assay used here.
The proteins studied here provide some interesting
leads concerning the pathophysiology of both CHD and
stroke. Their ability to enhance discrimination between
cases and controls, however, appears to be limited. For
example, when baseline values of these proteins were
added to a model that includes the variables used here
to control confounding (Table 3 analyses), the AUC for
CHD did not increase from its value of 0.670 with 95%
CI of (0.615, 0.726) without such addition. For stroke
there was some modest AUC increase from 0.645 (0.590,
0.700) without any such proteins added, to 0.663 (0.604,
0.718) when B2M was added, and to 0.665 (0.605, 0.722)
when IGFBP4 was added, based on analyses that randomly
divided the data into training and validation subsets with
the model fitted in the training set used to estimate AUC in
the validation set.
Using the same split sample approach, one can estimate
positive (PPV) and negative (NPV) predictive values for the
proteins for which there is evidence of disease risk associ-
ation at, say, a specificity of 80%. The PPV and NPV esti-
mates for CHD are 0.70 and 0.58, respectively, without
inclusion of the proteins studied here, and are essentially
unchanged when any of B2M, CFD, THBS1, or IGFBP1 is
added to the model. The corresponding estimated PPV and
NPV values of 0.62 and 0.54 without the proteins evaluated
increased slightly to 0.68 and 0.58 when B2M was added, to
0.66 and 0.57 when IGFBP4 was added, and to 0.64 and
0.56 when IGFBP2 was added to the regression model. The
highly overlapping distribution of the proteomic markers
between cases and controls (Table 2) prevents these mea-
sures from adding much to case versus control discrimin-
ation or, presumably, to personalized risk assessment. Even
though the discovery and validation phases of this work
took place in distinct cohorts, the WHI observational study
and clinical trial, respectively, the two cohorts were drawn
from essentially the same catchment population, and evalu-
ation of these findings in other populations will be useful.
The set of proteins studied here was limited by our
requirement of a commercially available ELISA and not
recognized as CHD or stroke risk markers. There were
several other proteins within FDR <0.20 bins that could
be evaluated, perhaps using multiple reaction monitor-
ing mass spectrometry. These proteins are listed in
Tables 1 and 2 of [17].
Conclusions
Proteomic discovery work has led to the identification of
plasma B2M, CFD, and THBS1 as novel risk markers for
CHD. Additionally, an increase in IGFBP1 over a 1-year
period also appears to convey CHD risk, and may be
relevant to the early elevation in CHD risk among
women initiating oral HT. This work has also led to the
identification of plasma B2M, IGFBP2, and especially
IGFBP4 as novel risk markers for stroke risk among
postmenopausal women.
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